Escalation of Vasopressors and Inotropes in Septic Shock

Initial Vasopressor Strategy

Start norepinephrine immediately after at least 30 mL/kg crystalloid fluid resuscitation fails to achieve hemodynamic stability, targeting a mean arterial pressure (MAP) ≥ 65 mmHg. 1
Insert an arterial catheter as soon as practicable for continuous blood‑pressure monitoring in every patient who requires vasopressor therapy. [1][2]

Add vasopressin at a fixed dose of 0.03 units/min when norepinephrine requirements reach 0.25–0.50 µg/kg/min, either to achieve the MAP target or to allow reduction of norepinephrine dose (“decatecholaminization”). 1
Never use vasopressin as monotherapy for the initial treatment of septic shock. 2
Reserve vasopressin doses >0.03–0.04 units/min for salvage therapy after failure of other agents. [1][2]
Epinephrine may be used as an alternative second‑line agent when an additional pressor is needed to maintain adequate blood pressure, either added to or substituted for norepinephrine. [1][2]

Dopamine should be limited to highly selected patients who have a low risk of tachyarrhythmias and who have absolute or relative bradycardia. [1][2]
Low‑dose dopamine for renal protection is strongly contraindicated. [1][2]
Phenylephrine should be avoided except in three specific situations: (1) serious arrhythmias caused by norepinephrine, (2) documented high cardiac output with persistent hypotension, or (3) as salvage after failure of combined inotrope/vasopressor regimens and low‑dose vasopressin. [1][2]

Initiate dobutamine (up to 20 µg/kg/min) in patients with persistent hypoperfusion despite adequate fluid loading and vasopressor support when cardiac dysfunction is evident. [1][2]
Titrate dobutamine to achieve perfusion endpoints (normalised lactate, improved central venous or mixed venous oxygen saturation, resolution of skin mottling) rather than to a fixed dose. 2
Immediately reduce or discontinue dobutamine if worsening hypotension or arrhythmias develop. 2

Assess peripheral perfusion markers (capillary refill time, skin mottling) together with blood pressure; normalising these markers may be more beneficial than lactate‑guided resuscitation alone. 3
Use central or mixed venous oxygen saturation (ScvO₂ > 70 % or SvO₂ > 65 %) as targets; values >80 % may paradoxically indicate microcirculatory dysfunction and poorer outcomes. 3
Serially evaluate capillary refill time and skin mottling; persistent abnormalities despite a normalized MAP suggest the need for additional intervention. 3
Avoid continued aggressive resuscitation aimed solely at normalising lactate when peripheral perfusion is already normal, as this practice is associated with increased mortality. 3
Individualise MAP targets based on peripheral perfusion—higher MAP may be required in patients whose peripheral perfusion remains abnormal at the standard MAP ≥ 65 mmHg target. 3

Administer hydrocortisone 200 mg/day only after adequate fluid resuscitation and vasopressor therapy have failed to restore hemodynamic stability. 2
Taper hydrocortisone once vasopressor support is no longer required. 2
Do not employ ACTH stimulation testing to select patients for hydrocortisone therapy. 2

Delaying the addition of a second vasopressor: early initiation of vasopressin at lower norepinephrine doses improves outcomes.
Routine use of vasopressin doses >0.03–0.04 units/min: such higher doses should be confined to salvage situations.
Starting inotropes without confirming cardiac dysfunction: inappropriate dobutamine use can increase myocardial oxygen demand and worsen outcomes.
Applying a universal MAP > 65 mmHg target without considering peripheral perfusion: individualized MAP goals may be necessary.
Continuing aggressive resuscitation when peripheral perfusion is already normal: this practice raises mortality risk.

Norepinephrine is recommended as the first‑line vasopressor for septic shock, with a target mean arterial pressure (MAP) of ≥ 65 mm Hg. Strong recommendation; moderate quality of evidence. 4

Begin norepinephrine promptly when adequate fluid resuscitation does not restore hemodynamic stability. Strong recommendation; moderate quality of evidence. 4
Set the initial hemodynamic goal at MAP ≥ 65 mm Hg. Moderate quality of evidence. 5

Add vasopressin at 0.03 units/min to raise MAP or to reduce the norepinephrine dose when norepinephrine alone is insufficient. Weak recommendation; moderate quality of evidence. 4
Do not use vasopressin as monotherapy for the initial treatment of septic shock. Moderate quality of evidence. 4
Reserve vasopressin doses higher than 0.03–0.04 units/min for salvage therapy only. Moderate quality of evidence. 6

Dopamine may be considered only in highly selected patients who have a low risk of tachyarrhythmias and who have absolute or relative bradycardia. Weak recommendation; low quality of evidence. 5
Phenylephrine is not recommended except in the following situations:
- When norepinephrine causes serious arrhythmias. 7
- When cardiac output is high with persistently low blood pressure. 8
- As salvage therapy after failure of other agents. Strong recommendation; moderate quality of evidence. 4

Consider a dobutamine infusion (up to 20 µg/kg/min) for patients with cardiac dysfunction who show persistent hypoperfusion despite adequate fluid loading and vasopressor therapy. Weak recommendation; low quality of evidence. 7
Administer hydrocortisone 200 mg/day for refractory shock when fluid resuscitation and vasopressor therapy fail to achieve hemodynamic stability. Moderate quality of evidence. 8

Place an arterial catheter as soon as practical in all patients receiving vasopressors. Weak recommendation; very low quality of evidence. 5

Do not use low‑dose dopamine for renal protection. Strong recommendation; high quality of evidence. 9